Clinical Trial ResultsPhase 3 RAISE study of ganaxolone in refractory status epilepticus did not meet the pre-defined stopping criteria at the interim analysis, casting doubts on the drug's efficacy.
Company's Financial HealthMarinus is reviewing cost-cutting measures to support their cash balance due to a bleak future for IV ganaxolone, signaling concerns over the company's financial stability.
Financial ForecastAnalyst lowers the risk-adjusted, DCF-derived price target from $15 to $12, reflecting significantly reduced expectations for the commercial success of IV ganaxolone.